ClinicalTrials.gg
RecruitingNCT07654179Updated Aug 7, 2026

Metformin as Adjunct Therapy in Depression-obesity Comorbidity: Clinical and Genetic Evaluation

An interventional study of Metformin and Antidepressant Therapy in Depression, Depressive Disorder and Overweight or Obesity, sponsored by Riphah International University. Recruiting at 2 sites in Pakistan. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Riphah International University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing metformin in Depression — 3 open to participants now, 3 under way, none of them phase 3. Metformin · Depression.

Planned enrollment
2nd of 10
200 · median 71
Started
2026
with 1 other
No phase
2 of 10
1 open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
Riphah International University

Among the 10 studies testing metformin in Depression, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2026, is one of 2 with no phase, and was the 10th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

3 of the 10 studies testing metformin in Depression are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing metformin in Depression, or all of them as a file.
02

Study summary

The patients with depression and obesity will receive add-on metformin with antidepressant therapy, which may result in greater improvement in depressive symptoms and BMI reduction compared to antidepressant monotherapy. NEGR1/RPL31P12 gene polymorphisms may influence the comparative efficacy of antidepressant monotherapy versus combination therapy (antidepressant + metformin) in Pakistani patients. Patients with certain variants may respond better or worse to antidepressants and may have different weight outcomes.

Read the detailed description

There is a substantial percentage of the Pakistani population who are both overweight/obese and depressed, with estimates from clinical samples averaging 25%. So, the personalized treatment approach for depression and obesity needs to be explored.

Obesity and depression commonly coexist and are associated with poorer health outcomes. Metformin, widely used for metabolic disorders and obesity, has shown potential antidepressant effects. However, evidence on its use as an adjunct to antidepressant therapy in patients with depression-obesity comorbidity remains limited, and the influence of genetic variants on treatment response is not well understood. This study aims to evaluate the effectiveness of adjunctive metformin and its association with NEGR1 and RPL31P12 genetic variants in this population.

03

Conditions studied

  • Depression
  • Depressive Disorder
  • Overweight or Obesity
  • Depressive Symptoms
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

INCLUSION CRITERIA Group I: Normal Controls Group II: Depression Group III: Obesity

Group IV and V:

  • Age ≥ 18 years
  • Both males and females
  • Recurrent depressive disorder (6A71) according to ICD-11,
  • Asian cut off: Obese and overweight ( \< 23)
  • BDI score ≥ 13 or PHQ score ≥ 4
  • Either medication-naïve or medication-free for at least 2 weeks before enrollment, or the patient did not take antidepressants during the last 7 days before study entry (discontinuation of effective medication to enable study participation is prohibited)
  • In case of non-psychotropic medication: The patient received stable pharmacological medication for at least 14 days before study entry (any changes in medication dose or frequency of therapy must be answered with no)

EXCLUSION CRITERIA Groups I-III: Negative Controls (Normal: no depression and Obesity for SNP comparison only)

  • Age less than 18
  • Dementia/ Mentally impaired who can not fill self report performas for inclusion criteria

Group IV: Positive Control (RCT patients)

  • Patients with comorbid conditions (HTN, CKD) if taking any drug for that condition.
  • The patient is not an employee of the investigator study site, or a family member of the employees or the investigator, or otherwise dependent on the sponsor, the investigator, or the investigator study site.
  • The patient did not participate in other interventional trials during the 6 months before and at the time of this trial. The patient does not have a history of non-response to antidepressants included in the study.
  • The patient has not given birth within the 6 months before study entry and is not breastfeeding
  • The patient did not receive treatment with ketamine, irreversible MAO inhibitor (e.g. tranylcypromine), electroconvulsive therapy (ECT) or other stimulatory treatments in the index episode.
  • The patient is not diagnosed with dementia and does not have moderate or severe impairment of general cognitive function according to clinical impression.
  • The patient does not meet the criteria for alcohol use disorder (: 303.90; ICD-10: F10.20) or substance use disorder (DSM-5: 304; ICD-10: F11.20 - F19.20) in DSM-5, and a urine/serum drug screening is negative (except for benzodiazepines and opiates).
  • The patient does not have:

    • A known allergy or against antidepressants included in the study
    • History of suicidal tendencies
    • Uncontrolled hepatic disorder, renal or cardiovascular disease
    • DM
    • Untreated hypothyroidism
    • History of myocardial infarction or stroke
    • Symptomatic peripheral arterial disease
    • Monogenic familial hypercholesterolemia
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Antidepressant Monotherapy

    Tab Sertraline 50 mg/day or Cap Duloxetine 60 mg/day or Tab Bupropion XL 150-300 mg/day

    Drug: Antidepressant Therapy

  • Experimental
    Adjunctive Metformin Therapy

    Tab Sertraline 50 mg/day + Metformin or Cap Duloxetine 60 mg/day + Metformin or Tab Bupropion XL 150-300 mg/day + Metformin

    Drug: Metformin · Drug: Antidepressant Therapy

Interventions

  • Tab 500-2000 mg/day (500 mg BD to 1000 mg BD)

    Also known as: Trade names: Glucophage, Neodipar

  • DrugAntidepressant Therapy

    Sertraline 50 mg/day or Duloxetine 60 mg/day or Bupropion XL 150-300 mg/day

    Also known as: Sertraline hydrochloride, Bupropion hydrochloride,

06

What researchers measure

Primary outcomes

  1. Change in Severity of the depression

    The change in the total PHQ-9 score between baseline and 4-weeks follow-up is the primary outcome measure. This measure is a patient-rated inventory of depressive symptoms. All items are scored on scales ranging from 0-3 and the sum of the scores provides the total score for the measure. On this scale, higher scores indicate poorer outcomes. Scores 9-19 and 20-27 are considered moderate and severe depression respectively.

    Time frame: 1 month

  2. Change in BMI

    Change in Body Mass Index (BMI): BMI will be measured at baseline and study completion and calculated as weight in kilograms divided by height in meters squared (kg/m²). The outcome will be assessed as the change in BMI from baseline. Asian BMI Classification: Underweight: \< 18.5 kg/m² Normal weight: 18.5-22.9 kg/m² Overweight: 23.0-24.9 kg/m² Obesity Class I: 25.0-29.9 kg/m² Obesity Class II: ≥ 30.0 kg/m² BMI reduction \< 1 kg/m²: Minimal change BMI reduction ≥ 1 kg/m²: Clinically meaningful improvement Weight loss ≥ 5% of baseline body weight: Clinically significant weight reduction associated with metabolic health benefits. A decrease in BMI from baseline and/or movement to a lower BMI category will be considered indicative of improvement in obesity-related outcomes.

    Time frame: 3 months

Secondary outcomes

  1. Change in Blood Pressure

    Change in Blood Pressure: Blood pressure will be measured in mmHg at baseline, 14 days, 28 days, one month and 3 months.. The outcome will be assessed as the change in systolic and diastolic blood pressure from baseline. Normal blood pressure is \<120/80 mmHg, elevated blood pressure is 120-129/\<80 mmHg, and high blood pressure is ≥130/80 mmHg. A reduction in blood pressure values from baseline will indicate improvement in cardiovascular health status.

    Time frame: 3 months

  2. Change in Blood Sugar Levels

    Change in Blood Sugar: Blood glucose levels will be measured at baseline, 14 days, 28 days, one month and 3 months. The outcome will be assessed as the change in blood glucose from baseline. Normal fasting blood glucose is 70-99 mg/dL, prediabetes is 100-125 mg/dL, and diabetes is ≥126 mg/dL. A reduction in blood glucose levels toward the normal range will indicate improvement in glycemic control, whereas increase will be monitored for safety

    Time frame: 3 months

  3. Change in Renal Function tests

    Change in Renal Function Tests: Renal function will be monitored by measuring serum creatinine and blood urea levels at baseline and study completion. The outcome will be assessed as the change in these parameters from baseline. Normal serum creatinine is approximately 0.6-1.2 mg/dL, while values \>1.2 mg/dL may indicate impaired renal function. Normal blood urea is approximately 15-40 mg/dL, while values \>40 mg/dL may suggest reduced kidney function or impaired renal clearance. An increase in serum creatinine or blood urea from baseline will be considered indicative of deterioration in renal function, whereas stable values within the normal range will indicate preserved renal function.

    Time frame: 3 months

  4. Change in Liver Function tests

    Change in Liver Function Tests (LFTs): Liver function will be monitored at baseline and study completion. The outcome will be assessed as the change in liver enzyme levels and bilirubin from baseline. Alanine Aminotransferase (ALT): Normal 7-56 U/L; elevated \>56 U/L may indicate liver injury. Aspartate Aminotransferase (AST): Normal 10-40 U/L; elevated \>40 U/L may indicate hepatic or muscle injury. Alkaline Phosphatase (ALP): Normal 44-147 U/L; elevated \>147 U/L may suggest cholestatic liver disease or biliary obstruction. Total Bilirubin: Normal 0.2-1.2 mg/dL; elevated \>1.2 mg/dL may indicate impaired liver function or biliary obstruction. Albumin: Normal 3.5-5.0 g/dL; decreased \<3.5 g/dL may indicate impaired hepatic synthetic function.

    Time frame: 3 months

  5. C - Reactive Proteins levels

    Change in C-Reactive Protein (CRP) Levels: CRP levels will be measured at baseline and study completion to assess systemic inflammation. The outcome will be assessed as the change in CRP levels from baseline. Normal: \< 3 mg/L Mildly elevated: 3-10 mg/L Moderately elevated: 10-50 mg/L Markedly elevated: \> 50 mg/L Severely elevated: \> 100 mg/L Decrease in CRP level: Indicates reduction in systemic inflammation. Stable CRP within normal range (\< 3 mg/L): Indicates absence of significant inflammation. Increase in CRP above normal range: Suggests worsening or persistent inflammatory activity.

    Time frame: 3 months

  6. Lipid Profile

    It will be measured at baseline and study completion to monitor safety of combination therapy. Total Cholesterol (TC): Desirable: \< 200 mg/dL, Borderline high: 200-239 mg/dL, High: ≥ 240 mg/dL Low-Density Lipoprotein Cholesterol (LDL-C): Optimal: \< 100 mg/dL, Near optimal: 100-129 mg/dL, Borderline high: 130-159 mg/dL, High: 160-189 mg/dL, Very high: ≥ 190 mg/dL High-Density Lipoprotein Cholesterol (HDL-C): Low: \< 40 mg/dL (men), \< 50 mg/dL (women), Protective: ≥ 60 mg/dL Triglycerides (TG): Normal: \< 150 mg/dL, Borderline high: 150-199 mg/dL, High: 200-499 mg/dL, Very high: ≥ 500 mg/dL Interpretation: Decrease in TC, LDL-C, and TG levels indicates improvement in lipid metabolism. Increase in HDL-C levels indicates a favorable cardiovascular risk profile. Lipid values remaining within the normal range throughout the study will be considered indicative of metabolic safety of the combination therapy.

    Time frame: 3 months

Other outcomes

  1. NEGR1 Polymorphism

    To identify genetic polymorphism in NEGR1 in the Pakistani population, genetic polymorphism in NEGR1 in the Pakistani population will be assessed by ARMS PCR assay.

    Time frame: 1 month

  2. RPL31P12

    To identify genetic polymorphism in RPL31P12 in the Pakistani population, genetic polymorphism in RPL31P12 in the Pakistani population will be assessed by ARMS PCR assay.

    Time frame: 1 month

07

Study locations

2 of 2 sites recruiting
  • Pakistan Railway Hospital
    Rawalpindi, Punjab Province 44000, Pakistan
    Recruiting
  • Afifa Siddique
    Rawalpindi, Punjab Province, Pakistan
    Recruiting
08

References and documents

Publications

  • Siddique A, Naeem U, Masood Khokhar M, Waheed Syed A, Iftikhar J, Amjad A. Impact of Demographic Factors on the Treatment Response of Antidepressant Therapy: A Descriptive Cohort Study from Pakistan. Tunis Med. 2025 Feb 5;103(2):201-205. doi: 10.62438/tunismed.v103i2.5280. PubMed 40096719 ↗
  • Ninomiya-Baba M, Matsuo J, Sasayama D, Hori H, Teraishi T, Ota M, Hattori K, Noda T, Ishida I, Shibata S, Kunugi H. Association of body mass index-related single nucleotide polymorphisms with psychiatric disease and memory performance in a Japanese population. Acta Neuropsychiatr. 2017 Oct;29(5):299-308. doi: 10.1017/neu.2016.66. Epub 2016 Dec 7. PubMed 27923415 ↗
  • Cheng YY, Yao Q, Miao Y, Guan W. Metformin as a potential antidepressant: Mechanisms and therapeutic insights in depression. Biochem Pharmacol. 2025 Mar;233:116773. doi: 10.1016/j.bcp.2025.116773. Epub 2025 Jan 31. PubMed 39894309 ↗
  • Choi WS, Song MK, Seo M, Woo YS, Bahk WM. Comparative efficacy and safety of liraglutide versus metformin, naltrexone/bupropion, and phentermine-topiramate in psychiatric patients. Ther Adv Psychopharmacol. 2026 Feb 18;16:20451253261419609. doi: 10.1177/20451253261419609. eCollection 2026. PubMed 41727810 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 11 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 11 months is below that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2026
First posted
Jun 17, 2026
StartActual
Jun 17, 2026
Primary completionEst.
Jun 11, 2027
CompletionEst.
Jun 11, 2027
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07654179
Responsible party
Sponsor
First posted
Jun 17, 2026
Start date
Jun 17, 2026
Primary completion
Jun 11, 2027 (estimated)
Completion
Jun 11, 2027 (estimated)
Last update
Aug 7, 2026

Study contacts

Afifa Siddique, PhD Scholar, MBBS, M.Phil
Contact
dr.afifa.siddique@gmail.com
+923175441910
Tayaba Farooq, MBBS, M.Phil
Contact
drafifa.one@gmail.com
+92 333 5244374
Afifa,Siddique, PhD Scholar, MBBS, M.Phil
principal investigator · Islamic International Medical College, Riphah International University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion